Last reviewed · How we verify
lysine acetylsalicylate
Lysine acetylsalicylate is a salt form of aspirin that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and provide analgesic, anti-inflammatory, and antiplatelet effects.
Lysine acetylsalicylate is a salt form of aspirin that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and provide analgesic, anti-inflammatory, and antiplatelet effects. Used for Acute pain and fever, Cardiovascular protection and antiplatelet therapy, Inflammatory conditions.
At a glance
| Generic name | lysine acetylsalicylate |
|---|---|
| Also known as | Flectadol, Cardirene, Inyesprin |
| Sponsor | Azienda Ospedaliera San Giovanni Battista |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent |
| Target | Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular; Pain management; Inflammation |
| Phase | FDA-approved |
Mechanism of action
As an acetylsalicylate derivative, this drug irreversibly inhibits COX-1 and COX-2 enzymes, reducing production of prostaglandins and thromboxane A2. The lysine salt formulation enhances solubility and absorption compared to standard aspirin, allowing for faster onset of action while maintaining the same mechanism of action for pain relief, inflammation reduction, and antiplatelet activity.
Approved indications
- Acute pain and fever
- Cardiovascular protection and antiplatelet therapy
- Inflammatory conditions
Common side effects
- Gastrointestinal bleeding or ulceration
- Dyspepsia
- Nausea
- Hypersensitivity reactions
- Increased bleeding risk
Key clinical trials
- Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome (PHASE3)
- Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction (PHASE1)
- Safety Profile Evaluation of TICagrelor Alone Compared to a Combination of Lysine Acetylsalicylate-Clopidogrel in the Context of Transcatheter Aortic Valve Implantation (TAVI) (PHASE3)
- Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) (PHASE3)
- Does Acetylsalicylic Acid Reduce the Mortality of Patients Admitted to an Intensive Care Unit (PHASE3)
- Endothelial Function Evaluation in Patients With PAOD Treated With Sulodexide + Conventional Treatment (CT) Vs CT Alone (PHASE3)
- Different Doses of IVIG for Kawasaki Disease (PHASE3)
- Studying the Efficacy of Aspirin & Clopidogrel in Healthy Subjects With Stable Coronary Artery Disease. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lysine acetylsalicylate CI brief — competitive landscape report
- lysine acetylsalicylate updates RSS · CI watch RSS
- Azienda Ospedaliera San Giovanni Battista portfolio CI